

Clinical Trial Protocol

Iranian Registry of Clinical Trials

20 Sep 2026

The Effectiveness of Inference-based Therapy Combined with Pharmacotherapy with Selective Serotonin Reuptake Inhibitors Compared to Selective Serotonin Reuptake Inhibitors Monotherapy in Treating Patients with Obsessive-Compulsive Disorder with Good Insight

Protocol summary

Study aim

The present study aims to compare the effectiveness of "inference-based therapy in combination with pharmacotherapy with selective serotonin reuptake inhibitors " to "selective serotonin reuptake inhibitors monotherapy" in the treatment of patients with obsessive-compulsive disorder with good insight.

Design

A clinical trial, with parallel groups, purposive sampling, phase 2 on 40 patients. Simple randomization was done.

Settings and conduct

The trial was conducted at Ebnesina Hospital in Shiraz. Participants were treated in two treatment groups. SSRIs were started at the lowest dose within the FDA-approved dose range and gradually increased, and three drugs were used: fluoxetine (ABIDI), sertraline (ABIDI), and fluvoxamine (Tehrandaru). IBT was also applied based on the IBT protocol during 24 45-minute sessions. The focus of this therapy is on eliminating obsessive doubt by overcoming the inferential confusion process. For this purpose, patients begin to change their obsessive narratives to non-obsessive narratives through therapeutic techniques during treatment. Inference-based therapy consists of 3 basic stages: education, intervention, and stabilization.

Participants/Inclusion and exclusion criteria

Inclusion criteria: 1. A primary diagnosis of OCD with good insight 2. Minimum level of education: High school diploma 3. Age between 18 to 50.4. Absence of suicidal risk/ current suicidal ideation. Exclusion criteria: 1. current Substance abuse 2. comorbid personality disorders, psychotic disorders, an organic mental disorder, a pervasive developmental disorder or mental retardation 3. evidence or diagnosis of bipolar disorder.

Intervention groups

There were 2 levels of intervention: 1. Pharmacotherapy

with SSRI and inference-based therapy 2. pharmacotherapy with SSRI

Main outcome variables

The severity of the obsessions and compulsions

General information

Reason for update

Shortening the title of article in order to submit in journal

Acronym

IRCT registration information

IRCT registration number: **IRCT20231029059893N1**

Registration date: **2023-11-25, 1402/09/04**

Registration timing: **prospective**

Last update: **2026-04-18, 1405/01/29**

Update count: **2**

Registration date

2023-11-25, 1402/09/04

Registrant information

Name

Samaneh Karbakhsh ravari

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 34 3372 3936

Email address

elahe.dori1364@gmail.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2023-11-11, 1402/08/20

Expected recruitment end date

2024-11-20, 1403/08/30

Actual recruitment start date

2023-12-02, 1402/09/11

Actual recruitment end date

2024-12-24, 1403/10/04

Trial completion date

2025-06-27, 1404/04/06

Scientific title

The Effectiveness of Inference-based Therapy Combined with Pharmacotherapy with Selective Serotonin Reuptake Inhibitors Compared to Selective Serotonin Reuptake Inhibitors Monotherapy in Treating Patients with Obsessive-Compulsive Disorder with Good Insight

Public title

Comparing the effect of "inference-based therapy and treatment with selective serotonin reuptake inhibitors" to "selective serotonin reuptake inhibitors" on obsessive-compulsive disorder

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

A primary diagnosis of obsessive compulsive disorder with good insight Minimum level of education :High school diploma Age between 18 to 50 Absence of suicidal risk/ current suicidal ideation

Exclusion criteria:

current substance abuse comorbid personality disorders, psychotic disorders, an organic mental disorder, a pervasive developmental disorder or mental retardation evidence or diagnosis of bipolar disorder.

Age

From **18 years** old to **50 years** old

Gender

Both

Phase

2

Groups that have been masked

No information

Sample size

Target sample size: **40**

Actual sample size reached: **40**

Randomization (investigator's opinion)

Not randomized

Randomization description**Blinding (investigator's opinion)**

Not blinded

Blinding description**Placebo**

Not used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics committee of Faculty of Education and Psychology -Shiraz University

Street address

Faculty of Education and Psychology, Shiraz University, Eram Square, Daneshjoo Blvd

City

Shiraz

Province

Fars

Postal code

71946-84334

Approval date

2023-04-18, 1402/01/29

Ethics committee reference number

IR.US.PSYEDU.REC.1402.022

Health conditions studied**1****Description of health condition studied**

Obsessive Compulsive Disorder

ICD-10 code

F42.2

ICD-10 code description

Mixed obsessional thoughts and acts

Primary outcomes**1****Description**

The patient's score on Yale-Brown Obsessive-Compulsive Scale

Timepoint

Before the start of the intervention and after the end of the intervention

Method of measurement

Yale-Brown Obsessive-Compulsive Scale

Secondary outcomes**1****Description**

The patient's score on the World Health Organization Quality of Life questionnaire - brief version

Timepoint

Before the start of the intervention and after the end of the intervention

Method of measurement

World Health Organization Quality of Life questionnaire - brief version

2

Description

The patient's score on Beck Depression Inventory

Timepoint

Before the start of the intervention and after the end of the intervention

Method of measurement

Beck Depression Inventory

3

Description

The patient's score on Beck Anxiety Inventory

Timepoint

Before the start of the intervention and after the end of the intervention

Method of measurement

Beck Anxiety Inventory

4

Description

The patient's score on Inferential Confusion Questionnaire, Extended Version

Timepoint

Before the start of the intervention and after the end of the intervention

Method of measurement

Inferential Confusion Questionnaire, Extended Version

Intervention groups

1

Description

First intervention group: Pharmacotherapy with selective serotonin reuptake inhibitors and inference-based therapy Inference-based therapy is a cognitive therapy that takes place in 24 sessions of 45 minutes over 6 months. The focus of this therapy is on resolving obsessive doubt by overcoming the process of inferential confusion. To this end, during treatment, patients begin to change their obsessive narratives to non-obsessive narratives through therapeutic techniques. Inference-based therapy consists of 3 basic steps: Education, Interventions & Consolidation. The Education phase consists of 4 steps: 1. Educating that most of OCD symptoms are caused by doubt 2. Focusing on reasoning before doubt (inferential confusion) and showing clients that doubt or obsession does not arise without a prelude 3. Exploring how obsessive doubt derives its power and value from a compelling narrative that logically leads to doubt 4. Addressing the selectivity nature of obsessions in OCD by introducing the construct of feared self. The intervention phase consists of: 1. Demonstrating the client that there is no direct here-and-now evidence that would support the OCD doubt & therefore, the OCD story is produced entirely subjectively 2. Demonstrating the client that since obsessive doubt arises purely from within the person and not an external source, it is %100 irrelevant to here and now 3. Assisting the client recognize the exact moment when they have left the

world of senses and entered the realm of imagination 4. Describing how obsessive doubt is always false -due to its opposition to reality And finally, the Consolidation phase:1. Encouraging the client to narrate a non-obsessive story 2.Introducing the client to many OCD tricks that make it seem as if the obsessive doubt is connected to reality. 3.Highlighting the selective nature of obsessive doubt besides the vulnerable self-theme that exists in doubt 4. Moving towards a life without OCD, developing a method to enable maintenance of gains and prevention of relapse. Pharmacotherapy was performed with three drugs, fluoxetine(ABIDI), sertraline(ABIDI), and fluvoxamine(Tehrandarou), which are FDA-approved for the treatment of OCD in terms of effectiveness and side effects. To minimize the side effects of the drugs, such as gastrointestinal side effects, dizziness, and other symptoms, treatment with SSRIs was started at a very low dose and over time, depending on the patient's tolerance to the drug side effects, the dose of the drugs was increased by the psychiatrist every 4-7 days until the target dose was achieved. A specific dose has been considered for each of the 4 drugs used: Recommended dose of sertraline: 50 to 200 mg per day Recommended dose of fluoxetine: 20 to 60 mg per day Recommended dose of fluvoxamine: 100 to 300 mg per day All drugs were used once a day, except for fluvoxamine, which was used twice a day due to its short half-life.

Category

Treatment - Other

2

Description

Second intervention group: Pharmacotherapy with selective serotonin reuptake inhibitors Pharmacotherapy was performed with three drugs, fluoxetine(ABIDI), sertraline(ABIDI), and fluvoxamine(Tehrandarou), which are FDA-approved for the treatment of OCD in terms of effectiveness and side effects. To minimize the side effects of the drugs, such as gastrointestinal side effects, dizziness, and other symptoms, treatment with SSRIs was started at a very low dose and over time, depending on the patient's tolerance to the drug side effects, the dose of the drugs was increased by the psychiatrist every 4-7 days until the target dose was achieved. A specific dose has been considered for each of the 4 drugs used: Recommended dose of sertraline: 50 to 200 mg per day Recommended dose of fluoxetine: 20 to 60 mg per day Recommended dose of fluvoxamine: 100 to 300 mg per day All drugs were used once a day, except for fluvoxamine, which was used twice a day due to its short half-life.

Category

Treatment - Other

Recruitment centers

1

Recruitment center

Name of recruitment center

Ebne Sina Hospital
Full name of responsible person
Samaneh Karbakhsh Ravari
Street address
Ebne Sina Hospital, next to Bostan 13 Aban, Hafez St,
Shiraz
City
shiraz
Province
Fars
Postal code
7144676541
Phone
+98 71 3228 9604
Email
samaneh.karbakhsh@hafez.shirazu.ac.ir
Web page address

Sponsors / Funding sources

1

Sponsor

Name of organization / entity
Shiraz university
Full name of responsible person
Bahram Hemmatinejhad
Street address
Faculty of Educational Sciences and Psychology,
Shiraz University, Eram Square, Daneshjoo Boulevard
City
Shiraz
Province
Fars
Postal code
71946-84334
Phone
+98 71 3613 4000
Email
pr@shirazu.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Shiraz university

Proportion provided by this source

50

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

2

Sponsor

Name of organization / entity
Shiraz University of Medical Sciences
Full name of responsible person
Hamid Mohammadi
Street address
Seventh Floor, Shiraz University of Medical Sciences
Central Building, Next to the Red Crescent,Zand Ave,
Shiraz
City
Shiraz
Province
Fars
Postal code
7134814336
Phone
+98 71 3235 7282
Email
vcrdep@sums.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Shiraz University of Medical Sciences

Proportion provided by this source

50

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Shiraz University

Full name of responsible person

Samaneh Karbakhsh Ravari

Position

PhD student

Latest degree

Master

Other areas of specialty/work

Psychology

Street address

Faculty of Educational Sciences and Psychology,
Shiraz University, Eram Square, daneshjoo Boulevard,

City

Shiraz

Province

Fars

Postal code

۸۴۳۳۴ - ۷۱۹۴۶

Phone

+98 71 3613 4000

Email

Person responsible for scientific inquiries

Contact

Name of organization / entity

Shiraz University

Full name of responsible person

Samaneh Karbakhsh Ravari

Position

PhD student

Latest degree

Master

Other areas of specialty/work

Psychology

Street address

Faculty of Educational Sciences and Psychology, Shiraz University, Eram Square, daneshjoo Boulevard

City

Shiraz

Province

Fars

Postal code

71946-84334

Phone

+98 71 3613 4000

Fax

Email

samaneh.karbakhsh@hafez.shirazu.ac.ir

Person responsible for updating data

Contact

Name of organization / entity

Shiraz University

Full name of responsible person

Samaneh Karbakhsh Ravari

Position

PhD student

Latest degree

Master

Other areas of specialty/work

Psychology

Street address

Faculty of Educational Sciences and Psychology, Shiraz University, Eram Square, daneshjoo Boulevard,

City

Shiraz

Province

Fars

Postal code

71946-84334

Phone

+98 71 3613 4000

Email

samaneh.karbakhsh@hafez.shirazu.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)

No - There is not a plan to make this available

Justification/reason for indecision/not sharing IPD

Despite attempts to anonymize data, there may be a risk of re-identification participants, which is unethical and violates the researcher's commitment to participants. There is also a concern that the original data may be valuable for the researcher's own future research.

Study Protocol

No - There is not a plan to make this available

Statistical Analysis Plan

No - There is not a plan to make this available

Informed Consent Form

No - There is not a plan to make this available

Clinical Study Report

No - There is not a plan to make this available

Analytic Code

No - There is not a plan to make this available

Data Dictionary

No - There is not a plan to make this available